Allurion Technologies announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program’s ongoing virtual guidance and support. In the study, 486 patients at a single, high-volume bariatric center were treated with the Allurion Balloon and assessed monthly with the Allurion App, Connected Scale, and Health Tracker as part of the Allurion Program. Over one year, participants were given virtual access to a team of registered dieticians. A weekly check-up was conducted for the first month, followed by biweekly check-ups for the subsequent three months, and monthly check-ups for the remaining eight months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies price target lowered to $2.50 from $5 at Chardan
- Allurion Technologies Faces NYSE Delisting Risk and Considers Remedies
- Allurion Technologies receives continued listing standards notice from NYSE
- Allurion Technologies reports Q2 EPS (5c), consensus (24c)
- ALUR Earnings this Week: How Will it Perform?